First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Our aim in this study was to evaluate the efficacy and safety of etoposide combined with
cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with
anlotinib for maintenance in extensive small cell lung cancer(ES-SCLC).